Skip to Main Content

Paper Details

Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.
Blood
18
2021
Author NameAffiliation
Jessica LeonardKnight Cancer Institute.
Jessica LeonardCenter for Hematologic Malignancies
Yoko KosakaKnight Cancer Institute.
Yoko KosakaOregon Health & Science University
Dorian LaTochaKnight Cancer Institute.
Adam J LambleKnight Cancer Institute.
Adam J LambleSeattle Children's Hospital
Brandon Hayes-LattinKnight Cancer Institute.
Brandon Hayes-LattinCenter for Hematologic Malignancies
Brian J DrukerKnight Cancer Institute.
Brian J DrukerCenter for Hematologic Malignancies
Jeffrey W TynerKnight Cancer Institute.
Jeffrey W Tyner
Bill H ChangKnight Cancer Institute.
Bill H ChangCenter for Hematologic Malignancies
Bill H ChangOregon Health & Science University
Evan F LindKnight Cancer Institute.
Evan F LindOregon Health & Science University
Evan F Lind
  • 1 - 19

Datasets

Release 1.2